Women living with HIV are high-risk for cervical intraepithelial neoplasia-2 (CIN2), a potentially pre-cancerous diagnosis. We characterized longitudinal variations in cervicovaginal lavage (CVL) chemokine/cytokine levels and their temporal relation with CIN2 and its progression.
N=104 HIV-positive women (age < 46) were selected from the Women’s Interagency HIV Study (WIHS). To avoid misclassification, we excluded women CIN3+ found within 6 months post-CIN2 diagnosis. CVLs were analyzed at 4 time points: (1) 0.5-1 year prior to CIN2, (2) at CIN2 diagnosis, (3) at progression/regression event, and (4) visit between CIN2 and progression/regression. We used Luminex assays to measure 34 cytokines/chemokines (normalized by total protein and log transformed). We used Bonferoni-adjusted T tests and logistic regression for analysis; multivariate analysis included adjustment for cervical treatment, smoking status, CD4 and HIV viral load.
Of the 104 women, 12 progressed to CIN3 (median 2.7 years), 63 regressed to CIN1/normal (median 1.5 years), and 29 had a subsequent CIN2 diagnosis (median 1.5 years). CIN2 treatment was received by 7 (58%) of CIN2 progressors, 20 (32%) of CIN2 regressors, and 13 (45%) of CIN2 stable women. The majority of women were African American (55%), current smokers at baseline (53%), with a median age of 34 years (no significant differences between groups). Anti-inflammatory cytokines were significantly lower in CIN2 regressors and CIN2 stable women at the CIN2 visit compared to CIN2 progressors (Figure 1). IL-27 was significantly elevated at the pre-CIN2 visit in progressors vs. regressors (p=0.03), no difference in IL-27 at visit where CIN2 was diagnosed. At CIN2 visit, IL-6 (p=0.05), IL-1a (p=0.03) and IL-10 (p=0.05) were elevated in progressors vs. regressors. Controlling for CIN2 treatment, smoking status, CD4 count, and HIV viral load, the odds of CIN2 progression was associated with higher IL-27 (aOR 1.41, 95% CI 1.23, 1.60), and IL-9 (aOR 1.39, 95% CI 1.08, 1.79), along with lowered IL-10 (aOR 0.53, 95% CI 0.34, 0.83) and IL-21 (aOR 0.83, 95% CI 0.71, 0.97), compared to CIN2 regressors.
We identified a group of cytokines, present at the time of CIN2 diagnosis, which may influence risk of CIN2 progression in HIV+ women. While IL-1a is strongly pro-inflammatory, IL-6, IL-9, IL-10, and IL-27 have inflammatory and anti-inflammatory activity-suggesting that a nuanced immune response to CIN2 may be key to its progression in HIV+ women.